Sun et al. (2023) showed that the eNAMPT/TLR4 inflammatory signaling pathway contributes significantly to MASLD severity and its progression to MASH and liver fibrosis, suggesting that neutralizing this pathway could reduce disease severity [42]. Here, TLR4 is linked to metabolic dysfunction-associated steatotic liver disease.